Interview with the CEO: Arcus Biosciences (NYSE:RCUS)
Terry Rosen, Ph.D., is the Chief Executive Officer of Arcus Biosciences. Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was Co-Founder and CEO of Flexus Biosciences, a company created to develop small molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion including milestones. Prior to Flexus, Dr. Rosen served as Vice President, Therapeutic Discovery at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Prior to joining Amgen, Dr. Rosen held several executive positions at Tularik as well as scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen serves on the Salk Institute board of trustees, the scientific advisory board of the University of Michigan Life Sciences Institute, the Berkeley Foundation board of trustees, the Caltech Biology and Bioengineering chair’s council and the board of the California Life Sciences Association. Profile
Word count: 4,144
TWST: Can you describe what you believe to be your primary assets and where they are in development?